Regardless, our functional in vitro and in vivo studies in CDK12-OE breast tumor models and in clinically relevant CDK12HIGH human breast cancer PDXs, clearly show that the unique metabolic requirements imposed by CDK12 overexpression are critical for CDK12-induced tumorigenesis, metastatic progression and therapy refractoriness. This evidence concerns the gene CDK12 and breast carcinoma.